Telaprevir
FDA-approved product (tablet, oral), marketed as Incivek.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Chronic hepatitis C virus infection
- Viral disease
Indications ChEMBL records as approved, from FDA and DailyMed labels.
- WHO therapeutic group
- Antivirals for treatment of hcv infections
- Anti-infective classification
- Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AP02
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA51.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli53.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae36.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis46.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Telaprevir with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Folic AcidExisting use: Acne, Anemia, Anemia (phenotype) and 8 more47.8% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Pafolacianine SodiumExisting use: Other diagnostic agents47.8% AI-predicted activityagainst K. pneumoniae1 registered study
- Rezafungin AcetateExisting use: Candidemia, Candidiasis, Candidiasis, Invasive47.6% AI-predicted activityagainst K. pneumoniae5 registered studies
- Simeprevir SodiumExisting use: Chronic hepatitis C virus infection47.3% AI-predicted activityagainst K. pneumoniaeNo documented evidence found
- Ergoloid MesylatesExisting use: Cardiovascular disease47.1% AI-predicted activityagainst K. pneumoniae2 registered studies
- TrabectedinExisting use: Cancer, Dedifferentiated liposarcoma, Leiomyosarcoma and 7 more47.1% AI-predicted activityagainst K. pneumoniae50+ registered studies
- LurbinectedinExisting use: Cancer, Neoplasm, Small cell lung carcinoma47.0% AI-predicted activityagainst K. pneumoniae50+ registered studies
- EptifibatideExisting use: Acute coronary syndrome, Acute myocardial infarction, Intermediate coronary syndrome and 2 more46.7% AI-predicted activityagainst K. pneumoniae35 registered studies
- Hydrocodone BitartrateExisting use: Cough, Drug dependence, Pain46.7% AI-predicted activityagainst K. pneumoniae50+ registered studies
- PalbociclibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 3 more46.4% AI-predicted activityagainst K. pneumoniae50+ registered studies
- AnidulafunginExisting use: Candidemia, Candidiasis, Peritonitis46.1% AI-predicted activityagainst K. pneumoniae43 registered studies
- TemsirolimusExisting use: Cancer, Clear cell renal carcinoma, Mantle cell lymphoma and 2 more46.1% AI-predicted activityagainst K. pneumoniae50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)
NCT01513941 · start 2012-04
Registered record
- Registry ID
- NCT01513941
- Conditions
- Chronic Hepatitis C
- Interventions
- Telaprevir; Ribavirin; Pegylated-Interferon-alfa-2a
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2012-04
- Completion
- 2014-06
- Enrolment
- 163
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionChronic Hepatitis CInterventionTelaprevir; Ribavirin; Pegylated-Interferon-alfa-2aPhasePhase 3Registry statusCompletedStudy to Examine Multiple Doses of TMC647055 in Combination With Telaprevir
NCT01582035 · start 2012-04
Registered record
- Registry ID
- NCT01582035
- Conditions
- Hepatitis C
- Interventions
- TMC647055; TMC647055; TVR; TVR; TVR; PegFN; RBV
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2012-04
- Completion
- 2013-11
- Enrolment
- 7
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHepatitis CInterventionTMC647055; TMC647055; TVR; TVR +3 morePhasePhase 1Registry statusCompletedA Study to Evaluate the Effect of Boceprevir and Telaprevir on Dolutegravir Pharmacokinetics in Healthy Adult Subjects (ING115697).
NCT01563328 · start 2012-03-01
Registered record
- Registry ID
- NCT01563328
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- DTG; BCV; TVR
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2012-03-01
- Completion
- 2012-05-01
- Enrolment
- 32
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInfection, Human Immunodeficiency VirusInterventionDTG; BCV; TVRPhasePhase 1Registry statusCompletedAn Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients
NCT01467505 · start 2012-02
Registered record
- Registry ID
- NCT01467505
- Conditions
- Hepatitis C
- Interventions
- Telaprevir; Ribavirin; Pegylated Interferon Alfa-2a; Immunosuppressant Regimen
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Terminated
- Start
- 2012-02
- Completion
- 2014-04
- Enrolment
- 61
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHepatitis CInterventionTelaprevir; Ribavirin; Pegylated Interferon Alfa-2a; Immunosuppressant RegimenPhasePhase 2Registry statusTerminatedTMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy
NCT01485991 · start 2012-02
Registered record
- Registry ID
- NCT01485991
- Conditions
- Hepatitis C
- Interventions
- TMC435; TVR
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2012-02
- Completion
- 2014-04
- Enrolment
- 771
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHepatitis CInterventionTMC435; TVRPhasePhase 3Registry statusCompletedTelaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C
NCT01467492 · start 2012-01
Registered record
- Registry ID
- NCT01467492
- Conditions
- Hepatitis C
- Interventions
- Telaprevir; Ribavirin; Pegylated Interferon Alfa-2a
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Terminated
- Start
- 2012-01
- Completion
- 2014-05
- Enrolment
- 121
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHepatitis CInterventionTelaprevir; Ribavirin; Pegylated Interferon Alfa-2aPhasePhase 4Registry statusTerminatedStudy Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection
NCT01492426 · start 2012-01
Registered record
- Registry ID
- NCT01492426
- Conditions
- Hepatitis C
- Interventions
- Daclatasvir; Telaprevir; Peginterferon alfa-2a; Ribavirin
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2012-01
- Completion
- 2014-03
- Enrolment
- 605
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHepatitis CInterventionDaclatasvir; Telaprevir; Peginterferon alfa-2a; RibavirinPhasePhase 3Registry statusCompletedA Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)
NCT01467479 · start 2011-12
Registered record
- Registry ID
- NCT01467479
- Conditions
- Hepatitis C
- Interventions
- Telaprevir; Ribavirin; Pegylated Interferon Alfa-2a; Highly Active Antiretroviral Therapy (HAART)
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Terminated
- Start
- 2011-12
- Completion
- 2014-02
- Enrolment
- 185
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHepatitis CInterventionTelaprevir; Ribavirin; Pegylated Interferon Alfa-2a; Highly Active Antiretroviral Therapy (HAART)PhasePhase 3Registry statusTerminatedChronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501
NCT01355289 · start 2011-11
Registered record
- Registry ID
- NCT01355289
- Conditions
- Thrombocytopenia
- Interventions
- Avatrombopag; Placebo; Pegylated interferon (PEG-IFN); Telaprevir; Ribavirin
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2011-11
- Completion
- 2014-05
- Enrolment
- 65
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionThrombocytopeniaInterventionAvatrombopag; Placebo; Pegylated interferon (PEG-IFN); Telaprevir +1 morePhasePhase 2Registry statusCompletedEfficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype
NCT01459913 · start 2011-11
Registered record
- Registry ID
- NCT01459913
- Conditions
- Hepatitis C, Chronic
- Interventions
- Telaprevir; Pegylated Interferon Alfa-2a; Ribavirin
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Terminated
- Start
- 2011-11
- Completion
- 2014-01
- Enrolment
- 239
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHepatitis C, ChronicInterventionTelaprevir; Pegylated Interferon Alfa-2a; RibavirinPhasePhase 3Registry statusTerminatedStudy to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care
NCT01359644 · start 2011-06
Registered record
- Registry ID
- NCT01359644
- Conditions
- Chronic Hepatitis C
- Interventions
- PSI-7977; Daclatasvir; Ribavirin
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2011-06
- Completion
- 2013-10
- Enrolment
- 350
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionChronic Hepatitis CInterventionPSI-7977; Daclatasvir; RibavirinPhasePhase 2Registry statusCompletedTelaprevir in HIV-HCV Coinfected Patients Who Had Previously Failed a Peginterferon-Ribavirin Regimen
NCT01332955 · start 2011-04
Registered record
- Registry ID
- NCT01332955
- Conditions
- Hepatitis C, Chronic; HIV Infection
- Interventions
- Telaprevir; pegIFN alfa-2a; Ribavirin
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2011-04
- Completion
- 2013-09
- Enrolment
- 70
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHepatitis C, Chronic; HIV InfectionInterventionTelaprevir; pegIFN alfa-2a; RibavirinPhasePhase 2Registry statusCompletedFrench Cohort of Therapeutic Failure and Resistances in Patients Treated With a Protease Inhibitor (Telaprevir or Boceprevir), Pegylated Interferon and Ribavirin
NCT01514890 · start 2011-02
Registered record
- Registry ID
- NCT01514890
- Conditions
- Chronic Hepatitis C
- Interventions
- Not recorded
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2011-02
- Completion
- 2014-03
- Enrolment
- 675
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionChronic Hepatitis CInterventionNot recordedPhaseNot recordedRegistry statusCompletedDrug-Drug Interaction Study Between Telaprevir and Buprenorphine
NCT01275599 · start 2011-01
Registered record
- Registry ID
- NCT01275599
- Conditions
- Hepatitis C; Opioid-Related Disorders
- Interventions
- telaprevir; buprenorphine/naloxone
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2011-01
- Completion
- Not recorded
- Enrolment
- 16
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHepatitis C; Opioid-Related DisordersInterventiontelaprevir; buprenorphine/naloxonePhasePhase 1Registry statusCompletedVX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection
NCT01241760 · start 2010-12
Registered record
- Registry ID
- NCT01241760
- Conditions
- Genotype 1 Chronic Hepatitis C; Treatment Naive
- Interventions
- Ribavirin; Telaprevir; Pegylated interferon alfa-2a; Telaprevir
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2010-12
- Completion
- 2012-11
- Enrolment
- 744
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionGenotype 1 Chronic Hepatitis C; Treatment NaiveInterventionRibavirin; Telaprevir; Pegylated interferon alfa-2a; TelaprevirPhasePhase 3Registry statusCompleted